Personalized medicine and disruptive innovation: Implications for technology assessment

Genetics in Medicine

Volumn 11, Issue 8, 2009, Pages 577-581

  Schulman, Kevin A ^a,b,c   Vidal, Ana Valverde ^a,b   Ackerly, D Clay ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; COMPUTER SYSTEM; EVOLUTIONARY ADAPTATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; MEDICAL PRACTICE; NOTE;

DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; HUMANS; INFORMATION DISSEMINATION; PERSONAL HEALTH SERVICES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 69549084947     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181ae0935     Document Type: Note

References (15)

1. Shumpeter JA. The theory of economic development. Cambridge: Harvard University Press, 1934.
2. Macher J, Richman B. Organisational responses to discontinuous innovation: a case study approach. Int J Innovat Manag 2004;8:87-113. (Pubitemid 38427000)
3. Christensen CM. The innovator's dilemma. Boston: Harvard Business School Press, 1997.
4. Curtis LH, Schulman KA. Overregulation of health care: musings on disruptive innovation theory. Law Contemp Probl 2006;69:195-206.
5. Eisenberg JM, Schwartz JS, McCaslin FC, Kaufman R, Glick H, Kroch E. Substituting diagnostic services. New tests only partially replace older ones. JAMA 1989;262:1196-1200. (Pubitemid 19206695)
6. Cooper RA, Henderson T, Dietrich CL. Roles of nonphysician clinicians as autonomous providers of patient care. JAMA 1998;280:795-802. (Pubitemid 28406754)
7. Berenson RA. A physician's view of managed care. Health Aff (Millwood) 1991;10:106-119.
8. Bodenheimer T. High and rising health care costs. Part 2: technologic innovation. Ann Intern Med 2005;142:932-937. (Pubitemid 40791809)
9. Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA. Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med 2005;165:2331-2336. (Pubitemid 41640844)
10. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-865.
11. Center for Devices and Radiological Health, Food and Drug Administration. Getting to market with a medical device. Available at: http://www.fda.gov/cdrh/ devadvice/3122.html. Accessed September 2, 2008.
12. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580. (Pubitemid 44200650)
13. Food and Drug Administration. Draft guidance for industry, clinical laboratories, and FDA staff: in vitro diagnostic multivariate index assays. Available at: http://www.fda.gov/cdrh/oivd/guidance/1610.pdf. Accessed September 2, 2008.
14. Centers for Medicare and Medicaid Services. Innovators' guide to navigating CMS. Available at: http://www.cms.hhs.gov/CouncilonTechInnov/ Downloads/InnovatorsGuide8-25-08.pdf. Accessed September 2, 2008.
15. Council on Technology and Innovation, Centers for Medicare and Medicaid Services. Available at: http://www.cms.hhs.gov/CouncilonTechInnov/. Accessed September 2, 2008.